David R. Bauer

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes…

Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by Flexion Therapeutics, Inc. of $201.25 million aggregate principal amount of its 3.375% convertible…

Davis Polk is advising VF Corporation on the sale of its Licensed Sports Group business to Fanatics, Inc. The transaction, which is expected to close in the second quarter of 2017, is…

Davis Polk advised the representatives of the underwriters in connection with the $75.9 million offering of 3,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock…

Davis Polk is advising First Data Corporation on the formation of a joint venture with FLEETCOR Technologies Inc. The new joint venture combines the gift card businesses of both companies…

Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…

Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…